Eli Lilly has been a huge winner in the last few months of 2025. New clinical data support its outlook in 2026, with large ...

Eli Lilly (LLY) has shown considerable rally potential, with several occurrences of its stock climbing over 30% in less than ...

Eli Lilly hiked its revenue growth guidance by 7%, while Novo Nordisk was forced to slash its targets by ~12%. See why I'm ...

Eli Lilly stock was on the outside looking in on Tuesday as shares of Novo Nordisk, its rival in diabetes and weight-loss ...

Eli Lilly and Novo Nordisk — the dominant players in obesity drug development — each submitted a new weight-loss drug to the ...

Eli Lilly is the clear leader in the burgeoning weight loss market. Its lineup and pipeline put it well ahead of even its ...

Abivax (ABVX) stock surged on Obefazimod trial success and takeover rumors. Learn if valuation risks now outweigh reward.

As investors look beyond mega-cap tech for the next leg of growth, pharma is quietly moving back into focus — and no two ...

Eli Lilly And Co (NASDAQ: LLY) shares are trading down on Tuesday as investors weigh the competitive landscape in the pharmaceutical sector.

Eli Lilly (NYSE:LLY) is rapidly establishing itself as the leader in GLP-1 treatments for weight loss. Its Zepbound injection ...

Eli Lilly seeks FDA approval for orforglipron, a once-daily pill shown in trials to help maintain weight loss after stopping ...

Eli Lilly is investing $6B in a Huntsville, Ala., plant to make weight-loss and other medicines. Here’s what we know about jobs and timeline.